On September 27, the event “Women in Biotech” organized by LithuaniaBIO took place. During the event, we heard 4 inspiring success stories from leaders in the biotechnology sector in Lithuania.
WOMEN IN BIOTECH is an inspiring platform created by LithuaniaBIO association encouraging women leadership in the life sciences field. Each year, the platform’s key event features distinguished female entrepreneurs, scientists, and activists who share their groundbreaking innovations and success stories in biotechnology, aiming to inspire the next generation of leaders and innovators. WOMEN IN BIOTECH aims to engage a diverse audience, from students to scientists and entrepreneurs, fostering experience-sharing, networking, and the development of long-lasting relationships.
Women in Biotech 2024 focused on a broader perspective of the biotech field, showcasing the wide array of roles and positions available within this dynamic sector. Event highlighted the various opportunities, essential skills and benefits associated with working in life sciences.
At this year’s event we heard inspiring stories from Dr. Ingrida Olendraitė, CSO at VUGENE; Dr. Eglė Radzevičienė, Chairman of the Board at Future Biomedicine Charity Fund; Kristina Vaivadaite, Client Partner and the Country Manager for Lithuania at Pedersen & Partners; and Dr. Edita Griniutė-Mištinienė, CEO at Profarma. Additionally, during the event, Dr. Ingrida Krogertė, Project Manager at the Lithuanian Innovation Center, gave a presentation on the topic: Women in STEAM: Challenges in Europe.
We thank the speakers and the event’s sponsors and partners: Caszyme, VUGENE, Exolitus, LAIMA, AAA Law, Vytautas Magnus university Agricultural Academy, and the Lithuanian Innovation Center.
Thank you to all who participated and see you next year!
The event is funded by the Research Council of Lithuania (LMT) under the funding measure “Support for Academic Associations” for the project “LithuaniaBIO international activities, event organization, and website update” agreement No. S-ACO-24-25.